Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL)
| العنوان: | Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL) |
|---|---|
| المؤلفون: | Ursula Haak, Astrid Franke, Ullrich Mey, Peter Richter, Rita Pasold, Stefanie Srock, Volker Lakner, Franz-Adolph Hoffmann, Sabine Neser, Gottfried Dölken, Thomas Ittel, Helga Schwenke, Ralph Naumann, Thomas Fietz, Andreas Neubauer, Michael Herold, Robert Rohrberg, Erika Kettner, Norbert Grobe, Mathias Freund, Dietger Niederwieser, Michael Assmann, Christian Klinkenstein, Dorothee Bleyl, Heiner Wolf, Detlev Hähling, Ullrich von Gruenhagen, Michael R. Clemens, H.-H. Wolf, Klaus Dachselt, Sabine Hahnfeld, Henning Eschenburg, Klaus Hoeffken |
| المصدر: | Blood. 104:584-584 |
| بيانات النشر: | American Society of Hematology, 2004. |
| سنة النشر: | 2004 |
| مصطلحات موضوعية: | medicine.medical_specialty, Chemotherapy, Mitoxantrone, business.industry, medicine.medical_treatment, Immunology, Follicular lymphoma, Cell Biology, Hematology, medicine.disease, Biochemistry, Gastroenterology, Surgery, Non-Hodgkin's lymphoma, hemic and lymphatic diseases, Internal medicine, medicine, Prednisolone, Mantle cell lymphoma, Rituximab, Progression-free survival, business, medicine.drug |
| الوصف: | Rituximab proved to be effective in relapsed and refractory indolent NHL as a single agent and generated impressive results in phase II studies in combination with chemotherapy. In a prospective randomized trial we compared the efficacy and toxicity of rituximab (375 mg/m² d 1) plus MCP-chemotherapy ( mitoxantrone 8 mg/m² d 3 + 4, chlorambucile 3 x 3 mg/m² d 3 – 7, prednisolone 25 mg/m² d 3 – 7 ) given every 28 days for a total of 8 cycles versus MCP (d 1 – 5) x 8 cycles alone in advanced indolent NHL and MCL. Efficacy endpoints included overall and complete response rates, event free survival, progression free survival, overall survival and toxicity. For response assessment classical definitions have been used. Between 10/98 and 09/03 we randomized 358 patients (pts) with advanced stage follicular lymphoma (FL) (grade 1 + 2), lymphoplasmacytic lymphoma and MCL to either R-MCP or MCP. The study arms are well balanced for all demographic factors. 201/358 pts (56%) had FL. Both regimens were well tolerated with a low incidence of serious adverse events. The overall response rate (RR) and the complete response rate (CR) for all pts was 85,5% and 42% in the R-MCP arm versus 65,5% and 20% in the MCP arm (p |
| تدمد: | 1528-0020 0006-4971 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::67cc847416484b206e1117aed57a247e https://doi.org/10.1182/blood.v104.11.584.584 |
| رقم الأكسشن: | edsair.doi...........67cc847416484b206e1117aed57a247e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|